Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 640 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 640 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total value of $100,012.80. Following the sale, the insider directly owned 56,397 shares in the company, valued at $8,813,159.19. This trade represents a 1.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Michael Alexander Smith also recently made the following trade(s):

• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $183,401.01.
• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $124,124.63.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $241,968.68.

Insmed Trading Down 3.0%

Insmed stock opened at $152.44 on Thursday. The stock has a 50-day moving average price of $177.10 and a 200 day moving average price of $159.66. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The stock has a market cap of $32.51 billion, a PE ratio of -24.63 and a beta of 1.11. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of research analyst reports. UBS Group dropped their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Guggenheim dropped their target price on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Cantor Fitzgerald upped their price target on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Redburn Partners set a $263.00 target price on Insmed in a research report on Thursday, December 4th. Finally, Morgan Stanley lifted their price target on shares of Insmed from $157.00 to $162.00 and gave the company an “equal weight” rating in a report on Friday, January 30th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $206.04.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently modified their holdings of the company. CoreCap Advisors LLC bought a new stake in shares of Insmed during the 4th quarter worth $27,000. GraniteShares Advisors LLC acquired a new stake in Insmed during the 4th quarter worth about $30,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Insmed in the 3rd quarter valued at approximately $29,000. Finally, SBI Securities Co. Ltd. grew its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares in the last quarter.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Large institutional holders increased or maintain sizable stakes (Vanguard, Artisan and others reported meaningful holdings increases in recent quarters), which supports structural demand for the stock and may limit downside. Read More.
• Positive Sentiment: Analyst coverage remains skewed to “Buy” with an average price target (~$206) well above the current trading level; several firms maintain or have raised targets (Goldman, Jefferies, others), indicating consensus upside potential if execution and results meet expectations. Read More.
• Neutral Sentiment: Insmed set its fourth‑quarter and full‑year 2025 earnings release and conference call for Thursday, Feb. 19 — a near‑term catalyst that will give investors fresh revenue, margin and guidance data to re‑rate the stock. Read More.
• Negative Sentiment: Multiple senior executives sold shares on Feb. 3 (CEO William Lewis sold 3,009 shares; CFO Sara Bonstein sold 748 shares; COO Roger Adsett sold 791 shares; and another officer sold 640 shares). While not uncommon for executives to trim positions for diversification or tax/liquidity reasons, clustered insider selling can be read negatively by the market and likely contributed to the stock moving lower. Read More.
• Negative Sentiment: The recent insider sales follow several prior sales by the CFO in January (multiple transactions), suggesting a pattern of executive selling this quarter rather than isolated trades; that pattern may increase short‑term selling pressure or investor caution ahead of results. Read More.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.